Named after the Netherlands’ first female doctor, Aletta Jacobs, the device is claimed to “optimise” blood draws.

Hastings Public Schools Foundation, Mary Lanning Healthcare Foundation, and Central Community College have all agreed to ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Vitestro today launched its Aletta autonomous robotic phlebotomy device (ARPD) that performs automated blood draws.

Phlebotomy Technicians are essential to proper healthcare worldwide as they are responsible for drawing blood needed for tests, donations, transfusions, and research. As the population ages and ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Aletta™, the world’s first Autonomous Robotic Phlebotomy Device™ (ARPD™) in action: two devices with two patients and one supervisor. Aletta is named in honor of Dr. Aletta Jacobs ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

This phlebotomy training programme in adult venepuncture will incorporate academic learning in addition to practical application. The period of training lasts up to 3 months, leading to an assessment ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...